



SCIBORG DAO

Solving death with synthetic replacements

CYBERNETICS NOW

SCIBORG

Artificial Organs

Artificial heart can last years



Brain Computer Interfaces

Paralized man walked



Ex Vivo Organ Perfusion

Human lung kept ex vivo for hours

FUTURE OF CYBERNETICS

SCIBORG

1. HEAD HOMEOSTASIS

15- 20 years - complex

Metabolic support of disembodied head can prevent mortality in 90% of cases and extend average lifespan



2. BRAIN IN A VAT

20 - 30 years - science fiction

Isolated brain in homeostasis connected to FullSence BCI and controlling a VR or real-world avatar





3. MERGER

30 - 50+ years - fantasy

Integration of brain tissue with synthetic systems to enable migration of the mind onto an artificial platform



HEAD PERFUSION: MODERN TECH SUITE

SCIBORG

Done | Someone is doing | Our todo

- Nutrients
- Buffers
- Hormonal signaling factors
- Metabolic factors
- Oxygen Carriers
- Immune system componnts
- Coagulation agents

Blood substitute/ bioproduction

- HeartLung function
- Kidney function
- Liver detox function

Homeostasis device
Sensor-guided feedback control
Real-time monitoring

Spinal Cord Termination Interface



DERISK 90% OF MORTALITY CAUSES

SCIBORG

Heart disease
702,880

Cancer (not connected with head)
±578,000

Accidents (unintentional injuries)
227,039

COVID-19
186,552

Chronic lower respiratory diseases
147,382

Kidney iseases
57,937

Diabetes
101,209

Chronic liver disease and cirrhosis
54,803

90%

2,052,000



10%

315,000

Alzheimer's disease
120,122

Cerebrovascular Diseases
(stroke)
165,393

Cancer
(oral cavity, pharynx, larynx, brain, and thyroid cancers)
±30,000

EMBODIMENT SUITE

SCIBORG



Sensoritmotor neural interface

NeuroRestore

ECATE

NEURALINK

BRAINGATE
TURNING THOUGHT INTO ACTION

Science

Robotic bodies

Boston Dynamics

CLONE

TESLA

Robotic skin

QMI Queen Mary Innovation

Caltech

東京大学
THE UNIVERSITY OF TOKYO

HEAD PERFUSION: HISTORICAL CONTEXT

SCIBORG

First experiments in keeping the alive head on the blood circulation system was done in USSR 1928 by Sergei Brukhonenko

- Mechanical blood pump
  (early heart-lung machine prototype)
- Manual lung ventilation (bellows)
- Circulating autologous blood

3.5 hours



OUR VISION: AUTONOMOUS CIRCTUIT

SCIBORG

- Living bone integration
- Next-gen oxygenator
- Detox module
- Recombinant plasma
- Nutrient infusion



Indefinite?



TARGET MARKETS

SCIBORG

1

REAL TIME BLOOD MONITORING & INFUSIONS
8 B$



LONG-TERM HEART-LUNG MACHINES
3.6 B$



2

BLOOD PURIFICATION

LONG-TERM ORGAN PERFUSION
2 B$



3

BLOOD BIOPRODUCTION
6.7 B$

NEURAL DRUGS SCREENING
8 B$

4

HEAD PERFUSION

XX% of all deaths

$ 600 bln opportunity



DEALFLOW: BIO-HYBRID BLOOD TUBES

SCIBORG DAO

The Problem: Synthetic tubing in ECMO and perfusion machines damages blood cells and activate clotting, limiting life or organ support viability.

The Solution: Coat synthetic tubing with living vascular endothelial cells. This mimics natural vessels, preserving cells and preventing clotting via glycocalyx and antithrombogenic factors.

Objectives:

- Develop endothelial coatings for silicone tubing (plasma, fibronectin, etc.)
- Validate cell viability, glycocalyx integrity, and RBC-protective markers
- Engineer autologous vessels from iPSC-derived endothelium
- Test under pulsatile flow and physiological shear
- Scale to branched vessel networks for multi-organ perfusion

An important step in unlocking long-term perfusion

Budget: $X | Timeline: 12 months



DEALFLOW: EXTENDED LIVER PERFUSION

SCIBORG DAO

The Problem: There is an organ shortage, yet many viable organs are discarded for logistical reasons.

The Solution: We're using AI real-time imaging and infusions to extend the time of organ preservation. Even 1 day of extension of liver preservation could save 10.000 extra people per year and bring $ 1 bln of capitalizaiton

Objectives:

- Develop mechanics for real-time phase-contrast supply to validate blood cells viability
- Develop longer-term oxygenation, that's less harmful for the blood
- Apply organ massage techniques
- Use hypersceptral imaging for assessing organs viability

Liver perfusion is an onramp to head perfusion

Budget: $X | Timeline: 12 months

SCIBORG AG



DEALFLOW: BIO-HYBRID BCI

SCIBORG DAO

TBA



DEALFLOW: INTER-HEMISPHERE BCI

SCIBORG DAO

TBA

東京大学
THE UNIVERSITY OF TOKYO





SCIBORG ECOSYSTEM



DAO



AG



WHY DAO?

SCIBORG

FUNDING PRE-CLINICAL & BASIC SCIENCE IN A VARIETY OF FIELDS

ASSEMBLING THE COMMUNITY OF CYBERNETICS

BUILDING THE INDUSTRY FOR FUTURE COMMERCIAL SPINOUTS

TEAM

SCIBORG

FOUNDING TEAM

Andrei Panferov
Execution

Tomer Landsberger, PhD
Science

Michele Diana, MD
MedTech

PERFUSION TEAM

Michael Lebenstein-Gumovski, MD
Neural Surgeon

Igor Dobrokhodov, PhD
Perfusion

Toptun Alexey Stanislavovich
Engineer

DAO CORE

Adam Gries
Ops, fundraising

Kai Micah Mills
Ops, Tokenomics



Eli Mohamad
Ops, Tokenomics

Kamen Shoylev
Legal

SCIENTIFIC ADVISORY

Dr. Michael Lebedev
Neural Interfaces

Dr. Sergio Canavero
Surgery

JOIN OUR PRIVATE ROUND

SCIBORG

DAO RAISE
40,000$ SAFT

FOR
PROMOTIONAL
ACTIVIRY

AG RAISE
€ 200.000 AT
VALUATION OF €
5.000.000

FOR POC

$SCBRG

COMING
SOON

TEXT ME

@TOMERLAN87

VISIT

www.sciborg.xyz